Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares dropped 3.4% during mid-day trading on Tuesday . The company traded as low as $25.04 and last traded at $25.09, with a volume of 774,522 shares changing hands. The stock had previously closed at $25.98.

SRPT has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $20.00 target price (down from $53.00) on shares of Sarepta Therapeutics in a research note on Sunday, April 24th. Jefferies Group reissued a “sell” rating and set a $7.00 target price on shares of Sarepta Therapeutics in a research note on Friday, May 6th. Leerink Swann reissued an “underperform” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, August 4th. Vetr lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $17.28 target price for the company. in a research note on Monday, May 23rd. Finally, Robert W. Baird reissued an “outperform” rating and set a $23.00 target price on shares of Sarepta Therapeutics in a research note on Monday, July 18th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $25.28.

The stock’s market cap is $1.19 billion. The stock’s 50 day moving average price is $23.14 and its 200-day moving average price is $18.56.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the previous year, the company earned ($0.87) EPS. Equities research analysts forecast that Sarepta Therapeutics Inc. will post ($5.16) EPS for the current fiscal year.

Other large investors recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock worth $32,354,000 after buying an additional 689,831 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock worth $1,841,000 after buying an additional 6,615 shares in the last quarter. Finally, Nationwide Fund Advisors raised its stake in shares of Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock worth $1,127,000 after buying an additional 2,471 shares in the last quarter.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.